Overview

Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel and Cisplatin in Patients With Solid Tumors

Status:
Completed

Trial end date:
2011-12-01

Target enrollment:

Participant gender:

Summary

Primary Objective: - To determine the maximum tolerated dose based on the incidence of dose limiting toxicity and the maximum administered dose of ombrabulin in combination with docetaxel and cisplatin administered every 3 weeks in patients with advanced solid tumors Secondary Objectives: - To assess the overall safety profile of the combination therapy - To characterize the pharmacokinetic profile of ombrabulin, its active metabolite RPR 258063, docetaxel and cisplatin in combination. - To evaluate anti-tumor activity of the combination therapy

Phase:

Phase 1

Details

Lead Sponsor:

Sanofi

Treatments:

Cisplatin
Docetaxel